RuiYi and arGEN-X Announce License Agreement

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

arGEN-X Inks $37M Series B

arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget